Prasugrel

Generic Name: Prasugrel

Brand Names: Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀FNO_₃S

CAS Number: 150322-43-3

Unique Ingredient Identifier: 34K66TBT99

Background: Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on ...

Indication: 用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。

Associated Conditions: Cardiovascular Events

Associated Therapies: -

Clinical Trials

Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)

Phase 4

Terminated

Conditions: Thrombosis
Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2012-06-06

Last Posted Date: 2018-04-26

Lead Sponsor: Indiana University

Target Recruit Count: 67

Registration Number: NCT01612884

Locations: 🇺🇸
Eskenazi Health, Indianapolis, Indiana, United States
🇺🇸
Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States

Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention

Phase 3

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2012-06-01

Last Posted Date: 2014-12-23

Lead Sponsor: Dong-A University

Target Recruit Count: 76

Registration Number: NCT01609647

Locations: 🇰🇷
DongA University Hospital, Busan, Korea, Republic of

The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency

Phase 3

Conditions: Coronary Artery Disease

Interventions: Drug: Aspirin
Drug: Tirofiban
Drug: Clopidogrel
Drug: Prasugrel

First Posted Date: 2012-05-15

Last Posted Date: 2012-05-15

Lead Sponsor: Prince Sultan Cardiac Center, Adult Cardiology Department.

Target Recruit Count: 200

Registration Number: NCT01598337

Locations: 🇸🇦
Prince Sultan Cardiac Center, Riyadh, Saudi Arabia

Study of Prasugrel in Korean Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Prasugrel

First Posted Date: 2012-05-04

Last Posted Date: 2012-10-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT01591317

Locations: 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of

Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis

Phase 3

Completed

Conditions: Coronary Artery Bypass

Interventions: Drug: Prasugrel
Drug: Placebo

First Posted Date: 2012-03-22

Last Posted Date: 2019-10-30

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 84

Registration Number: NCT01560780

Locations: 🇺🇸
Jesse Brown VA Medical Center Community-Based Outpatient Clinic Lake Side Divison, Chicago, IL, Chicago, Illinois, United States
🇺🇸
North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States
🇺🇸
San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States

and more 1 locations

High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients

Phase 3

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2012-03-05

Last Posted Date: 2013-12-11

Lead Sponsor: University of Roma La Sapienza

Target Recruit Count: 81

Registration Number: NCT01543932

Locations: 🇮🇹
Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy

PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus

Phase 3

Completed

Conditions: ST-Elevation Myocardial Infarction

Interventions: Drug: ticagrelor
Drug: prasugrel

First Posted Date: 2012-02-10

Last Posted Date: 2017-06-28

Lead Sponsor: Gennaro Sardella

Target Recruit Count: 50

Registration Number: NCT01531114

Locations: 🇮🇹
Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy

Rapid Activity of Platelet Inhibitor Drugs Study

Phase 4

Completed

Conditions: ST-segment Elevation Myocardial Infarction

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2012-01-13

Last Posted Date: 2014-09-25

Lead Sponsor: Careggi Hospital

Target Recruit Count: 50

Registration Number: NCT01510171

Locations: 🇮🇹
Careggi Hospital, Florence, Italy

Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention

Phase 3

Completed

Conditions: Acute Coronary Syndromes

Interventions: Drug: PRASUGREL
Drug: Clopidogrel

First Posted Date: 2012-01-09

Last Posted Date: 2012-05-23

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 187

Registration Number: NCT01505790

Locations: 🇫🇷
Assistance Publique Hopitaux de Marseille, Marseille, France

Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity

Phase 4

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Prasugrel
Drug: Clopidogrel reloading

First Posted Date: 2011-12-16

Last Posted Date: 2014-10-08

Lead Sponsor: University of Pecs

Target Recruit Count: 147

Registration Number: NCT01493999

Locations: 🇭🇺
University of Pécs, Heart Institute, Pécs, Hungary

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy